Research development of DLC-1 gene in hepatocellular carcinoma

doi:10.3877/cma.j.issn.1674-0793.2013.05.015

Abstract

Abstract:

Deleted in liver cancer 1(DLC-1), a tumor suppressor gene, is separated from primary liver cancer tissue. Its expression is down-regulated or absent in a variety of human malignant tumors and also a tumor suppressor gene hot in recent researches. This article will firstly introduce the structure and biological function of the DLC-1 gene, and then discuss the mechanism of the DLC-1 gene in the development of liver cancer, combined with the latest research achievements at present about DLC-1 in hepatocellular carcinoma. The last part is more in-depth discussions of the DLC-1 expression in HCC missing genetics and epigenetic mechanisms.

Key words: DLC-1, Hepatocellular carcinoma, Tumor suppressor gene

Peng PENG. Research development of DLC-1 gene in hepatocellular carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(05): 393-396.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2013.05.015

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2013/V07/I05/393

References 30

1	Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol, 2009, 27(9): 1485-1491.
2	Yuan BZ, Miller MJ, Keck CL, et al. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 1998, 58(10): 2196-2199.
3	Ko FC, Yeung YS, Wong CM, et al. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. Liver Int, 2010, 30(1): 139-148.
4	Low JS, Tao Q, Ng KM, et al. A novel isoform of the 8p22 tumor suppressor gene DLC1 suppresses tumor growth and is frequently silenced in multiple common tumors. Oncogene, 2011, 30(16): 1923-1935.
5	Heasman SJ, Ridley AJ. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol, 2008, 9(9): 690-701.
6	Grise F, Bidaud A, Moreau V. Moreau, Rho GTPases in hepatocellular carcinoma. Biochim Biophys Acta, 2009, 1795(2): 137-151.
7	Qiao F, Bowie JU. The many faces of SAM. Sci STKE, 2005, 2005(286): re7.
8	Kim TY, Healy KD, Der CJ, et al. Effects of structure of Rho GTPase-activating protein DLC-1 on cell morphology and migration. J Biol Chem, 2008, 283(47): 32 762-32 770.
9	Zhong D, Zhang J, Yang S, et al. The SAM domain of the RhoGAP DLC1 binds EF1A1 to regulate cell migration. J Cell Sci, 2009, 122(Pt 3): 414-424.
10	Strauss JF 3rd, Kishida T, Christenson LK, et al. START domain proteins and the intracellular trafficking of cholesterol in steroidogenic cells. Mol Cell Endocrinol, 2003, 202(1-2): 59-65.
11	Zhang M, Liu P, Dwyer NK, et al. MLN64 mediates mobilization of lysosomal cholesterol to steroidogenic mitochondria. J Biol Chem, 2002, 277(36): 33 300-33 310.
12	Li G, Du X, Vass WC, et al. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK). Proc Natl Acad Sci U S A, 2011, 108(41): 17 129-17 134.
13	Ng IO, Liang ZD, Cao L, et al. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res, 2000, 60(23): 6581-6584.
14	Wong CM, Lee JM, Ching YP, et al. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 2003, 63(22): 7646-7651.
15	Zhou X, Zimonjic DB, Park SW, et al. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. Int J Oncol, 2008, 32(6): 1285-1291.
16	Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene, 2004, 23(6): 1308-1313.
17	Yuan BZ, Jefferson AM, Millecchia L, et al. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells. Exp Cell Res, 2007, 313(18): 3868-3880.
18	Ogawa T, Tashiro H, Miyata Y, et al. Rho-associated kinase inhibitor reduces tumor recurrence after liver transplantation in a rat hepatoma model. Am J Transplant, 2007, 7(2): 347-355.
19	段炜，顾勇，杨艳, 等. DBC1在肝癌组织中的表达及临床意义[J/CD]. 中华临床医师杂志：电子版, 2012, 6(9): 2370-2373.
20	Wu J, Li Y, Fan X, et al. Analysis of gene expression profile of periodontal ligament cells subjected to cyclic compressive force. DNA Cell Biol, 2011, 30(11): 865-873.
21	Roessler S, Long EL, Budhu A, et al. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival. Gastroenterology, 2012, 142(4): 957-966.e12.
22	Goodison S, Yuan J, Sloan D, et al. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res, 2005, 65(14): 6042-6053.
23	Wong CM, Yam JW, Ching YP, et al. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer Res, 2005, 65(19): 8861-8868.
24	Holeiter G, Heering J, Erlmann P, et al. Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res, 2008, 68(21): 8743-8751.
25	Durkin ME, Avner MR, Huh CG, et al. DLC-1, a Rho GTPase-activating protein with tumor suppressor function, is essential for embryonic development. FEBS Lett, 2005, 579(5): 1191-1196.
26	Dong X, Zhou G, Zhai Y, et al. Association of DLC1 gene polymorphism with susceptibility to hepatocellular carcinoma in Chinese hepatitis B virus carriers. Cancer Epidemiol, 2009, 33(3-4): 265-270.
27	Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev, 2008, 22(11): 1439-1444.
28	Kim TY, Jong HS, Song SH, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene, 2003, 22(25): 3943-3951.
29	Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet, 2003, 140(2): 113-117.
30	Banaudha K, Kaliszewski M, Korolnek T, et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology, 2011, 53(1): 53-61.

[1]	Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.
[2]	Miao Li, Lianhua Zhu, Peng Han, Bo Jiang, Xiang Fei. Evaluation of relationsip between vascular morphology and risk factors for hepatocellular carcinoma by high-frame-rate contrast-enhanced ultrasound [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 911-915.
[3]	Jie Dong, Song Yang, Hao Yang, Xiang Chen, Wanli Zhang. Relationship between hypermethylation of ACACB gene and clinicopathological factors and survival of hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(06): 433-437.
[4]	Wei Huang, Qi Liu, Liuhua Chen, Chaxiang Teng, Zhejian Ou, Hanxiao Liu, Jiancong Chen, Kunsong Zhang. Identification of a pyroptosis-related lncRNA signature as a novel prognostic biomarker for hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 357-365.
[5]	Leilei Zhu, Bing Zhu, Jiajia Guan, Jie Luo, Qun Hang, Jun Fu. Detection value of the promoter methylation of the PAX5, SEPT9, and WIF-1 genes in primary gastric cancer [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(04): 288-292.
[6]	Rongchang Wang, Qifeng Ou, Jinjie Huang, Caiqin Wang, Qian Wang, Xiaohui Huang. Expression of miR-145-5p in hepatocellular carcinoma and its clinical significance [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(03): 197-202.
[7]	Xiyan Zheng, Zheng Zhou, Fangping He, Zhiqun Lin, Fei Du, Qin Xie, Shaoping Wang, Xianjie Shi. Risk factors for the prognosis of metabolic syndrome and hepatitis B virus related hepatocellular carcinoma [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 104-109.
[8]	Mingxiu Ma, Feng Xu, Kailing Xie, Yaming Guo, Tonghui Lu, Chaoliu Dai. Preoperative alkaline phosphatase to prealbumin ratio predicting the prognosis of hepatocellular carcinoma after hepatectomy [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 99-103.
[9]	Hongxiang Yin, Jiakang Duan, Bowen Jiang, Yi Tan. Predictive value of combined systemic immunoinflammatory index and prognostic nutritional index on the prognosis of patients with hepatocellular carcinoma after radical resection [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(02): 93-98.
[10]	Qijian Yu, Zhe Yang, Shusen Zheng. Current status and progress of research on prevention of tumor recurrence after liver transplantation for hepatocellular carcinoma [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 171-179.
[11]	Wenhua Zhang, Cui Tao, Tiansong Hu. Clinicopathological characteristics of pedunculated hepatocellular carcinoma in different sites and its effects on postoperative intrahepatic recurrence and prognosis [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 651-655.
[12]	Baoru Hu, Naijian Shang, Di Gao. DCE-MRI and DWI findings of advanced hepatocellular carcinoma and their correlation with prognosis after immunotherapy [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 399-403.
[13]	Fengyun Wu, Xin Teng, Lianjuan Liu. Diagnostic value of high-frequency ultrasonography and enhanced magnetic resonance for primary hyperdifferentiated hepatocellular carcinoma of different diameters [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 404-408.
[14]	Zhongbai Liu, Yongjun Ren. Current status and progress of interventional therapy for hepatocellular carcinoma [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 111-115.
[15]	Xueqing Huang, Nan Wei, Tianpeng Jiang, Tianzhi An, Min Xu, Shi Zhou. Clinical study of TACE for hepatocellular carcinoma by ultrasound-guided transdistal radial artery approach [J]. Chinese Journal of Interventional Radiology(Electronic Edition), 2023, 11(03): 251-256.

Please choose a citation manager

Content to export